Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Zhirong Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9118-5394; OpenAlex author ID A5100602197. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. 3-Indoleacetic Acid-Modified Chondroitin Sulfate-Mediated Paclitaxel Nanocrystal Assembly for the Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acsami.4c19450↗
  2. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming. Last author DOI 10.1016/j.actbio.2022.03.050↗
  3. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles. Co-author DOI 10.1016/j.actbio.2021.05.002↗
  4. Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression. Co-author DOI 10.1016/j.ejpb.2021.05.014↗
  5. Comprehensively enhanced delivery cascade by transformable beaded nanofibrils for pancreatic cancer therapy. Co-author DOI 10.1039/d1nr02017j↗
  6. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Co-author DOI 10.7150/thno.60437↗
  7. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therap… Co-author DOI 10.1016/j.jconrel.2020.02.011↗
  8. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2019.05.019↗
  9. Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy. Co-author DOI 10.1039/c9nr03684a↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qin He · 6 shared papers, 2019–2022 · strength 0.74
  2. Man Li · 6 shared papers, 2019–2021 · strength 0.69
  3. Yao Shi Fu · 2 shared papers, 2019–2025 · strength 0.36
  4. Yueting Zhu · 1 shared paper, 2025 · strength 0.27
  5. Qinglin Sheng · 2 shared papers, 2021 · strength 0.24
  6. Qianwen Yu · 2 shared papers, 2020–2021 · strength 0.22
  7. Miao Deng · 2 shared papers, 2019–2021 · strength 0.20
  8. Xiaoxiao Chen · 2 shared papers, 2019–2021 · strength 0.20
  9. Rongping Zhang · 1 shared paper, 2022 · strength 0.17
  10. Ting Zhao · 1 shared paper, 2022 · strength 0.17
  11. Zhengze Lu · 1 shared paper, 2021 · strength 0.14
  12. Ting Li · 1 shared paper, 2021 · strength 0.13
  13. Qin Shu He · 1 shared paper, 2021 · strength 0.13
  14. Jiao He · 1 shared paper, 2021 · strength 0.12
  15. Weiyuan John Kao · 1 shared paper, 2019 · strength 0.10
  16. Ying Hu · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.